Endocrinology and Metabolic Disorders

Vertex leads in CRISPR Therapeutics partnership with USD 900 Million upfront Vertex has boosted a deal with CRISPR Therapeutics to USD 900 million upfront as the companies compete against bluebird bio to the market with a novel gene-editing therapy for sickle cell disease and beta-thalassemia called CTX001. Boston-based Vertex will reimburse CRISPR USD 900 million upfront with a potential for USD 200 million in milestone payments if the therapy is granted. Vertex will be responsible for 60% of the program costs and receive the same in profits from future global sales of CTX001. The new deal is a 10% increase from the former agreement. CTX001 is under developm...